XEPTAGEN S.p.A., Via delle Industrie 9, Marghera Venezia, Italy.

This email address is being protected from spam bots, you need Javascript enabled to view it

Several reports indicate that the main biomarkers for liver and colorectal cancer circulating in the blood stream associate with immunoglobulin M (IgM) to form stable complexes that show increased diagnostic relevance compared to circulating free biomarkers.

To further investigate the association between cancer biomarkers and IgM, we assessed the presence of prostate-specific antigen (PSA) as IgM complexes in sera of patients with prostate cancer (PC) or benign prostatic hyperplasia (BPH) in comparison with PSA measurements.

PSA-IgM levels were significantly elevated in 40% (20/50) and 12% (6/51) of PC and BPH patients, respectively, compared to 22% (11/50) and 29% (15/51) of PSA positive patients in the same groups. Detection of cancer markedly increased from 22 to 60% by co-determination of both markers (30/50 patients). Significantly elevated levels of PSA-IgM were found in 13 out of 30 patients affected by PC with a PSA value between 4 and 10 ng/mL and only in 4 out of 34 BPH patients in the same PSA range.

The results are the first evidence of the occurrence of PSA-IgM complexes in patients with prostate cancer. The gain achieved in cancer detection by using the combination of PSA and PSA-IgM suggests that PSA-IgM could be a complementary serological marker of prostate cancer.

Written by
Beneduce L, Prayer-Galetti T, Giustinian AM, Gallotta A, Betto G, Pagano F, Fassina G.

Reference
Cancer Detect Prev. 2007;31(5):402-7. Epub 2007 Nov 26
doi:10.1016/j.cdp.2007.10.005

PubMed Abstract
PMID:18035503

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!